Influence of GGCX genotype on warfarin dose requirements in Chinese patients

Thrombosis Research

Volumn 127, Issue 2, 2011, Pages 131-134

  Huang, Sheng Wen ^a   Xiang, Dao Kang ^a   Huang, Ling ^a   Chen, Bao Lin ^a   An, Bang Quan ^a   Li, Gui Fang ^a   Luo, Zhen Yuan ^a  

^a GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Chinese; GGCX; Polymorphism; Warfarin: DHPLC

Indexed keywords

GENOMIC DNA; MEMBRANE ENZYME; PROTEIN GGCX; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CHINA; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBON-CARBON LIGASES; CHINA; DNA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN; YOUNG ADULT;

EID: 79151469381     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.10.027     Document Type: Article

References (14)

1. M. Wadelius, and M. Pirmohamed Pharmacogenetics of warfarin: current status and future challenges Pharmacogenomics J 7 2007 99 111
2. A.K. Daly, and B.P. King Pharmacogenetics of oral anticoagulants Pharmacogenetics 13 2003 247 252
3. A.M. Hall, and M.R. Wilkins Warfarin: a case history in pharmacogenetics Heart 91 5 2005 May 563 564
4. S.W. Huang, H.S. Chen, X.Q. Wang, L. Huang, D.L. Xu, and X.J. Hu Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients Pharmacogenet Genomics 19 3 2009 226 234
5. E.A. Sconce, T.I. Khan, H.A. Wynne, P. Avery, L. Monkhouse, and B.P. King The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 2005 2329 2333
6. M. Wadelius, L.Y. Chen, N. Eriksson, S. Bumpstead, J. Ghori, and C. Wadelius Association of warfarin dose with genes involved in its action and metabolism Hum Genet 121 2007 23 34
7. M. Wadelius, L.Y. Chen, K. Downes, J. Ghori, S. Hunt, and N. Eriksson Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J 5 2005 262 270
8. R. Loebstein, M. Vecsler, D. Kurnik, N. Austerweil, E. Gak, and H. Halkin Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9 Clin Pharmacol Ther 77 5 2005 365 372
9. E.A. Sconce, A.K. Daly, T.I. Khan, H.A. Wynne, and F. Kamali APOE genotype makes a small contribution to warfarin dose requirements Pharmacogenet Genomics 16 8 2006 609 611
10. R. González-Conejero, J. Corral, V. Roldán, and V. Vicente Gamma-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol Thromb Res 122 3 2008 429 431
11. M.J. Rieder, A.P. Reiner, and A.E. Rettie Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose J Thromb Haemost 5 11 2007 2227 2234
12. E. Shikata, I. Ieiri, S. Ishiguro, H. Aono, K. Inoue, and T. Koide Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gammaglutamyl carboxylase) gene variants with warfarin sensitivity Blood 103 2004 2630 2635
13. M. Wadelius, L.Y. Chen, J.D. Lindh, N. Eriksson, M.J. Ghori, and S. Bumpstead The largest prospective warfarin-treated cohort supports genetic forecasting Blood 113 4 2009 784 792
14. G.M. Tan, E. Wu, Y.Y. Lam, and B.P. Yan Role of warfarin pharmacogenetic testing in clinical practice Pharmacogenomics 11 3 2010 439 448